While there are limited or no information on the relationship between TMX treatment and hepatic IL-6 expression, earlier reports have shown that COX-2 may play a vital role as a predictor of adverse effects of TMX in breast cancer patients [58]. The gene discussed is PTGS2; the disease is breast cancer.